London, England -- (SBWIRE) -- 03/22/2012 -- GlobalData estimates that the global leiomyosarcoma therapeutics market was valued at $53.4m in 2011, and is forecast to grow at a high Compound Annual Growth Rate (CAGR) of 9.2% over the next seven years to reach $108.2m by 2019. This fast growth is primarily attributed to the strength of the leiomyosarcoma pipeline, which contains five first-in-class molecules in the late stage of development.

These molecules are expected to be launched during the forecast period, with ridaforolimus, the New Drug Application (NDA) of which is filed by Merck & Co., Ltd., expected to hit the market in 2013. All of the novel targeted therapies (Votrient (pazopanib) in 2014, TH-302 in 2015, Yondelis (trabectedin) and Halaven (eribulin mesylate) in 2016) are also expected to be launched in the forecast period. These will replace the existing off-label generic drugs for the treatment of leiomyosarcoma, and will emerge to be the market leaders.

The leiomyosarcoma therapeutics market is relatively small compared to other cancers, but an untapped opportunity exists within it for companies with novel approaches to systemic therapy and local control, and therapies with improved toxicity profiles.

Competition in the global leiomyosarcoma therapeutics market is presently weak, as the current options for advanced or recurrent leiomyosarcoma are limited, with only five or six off-label drugs -doxorubicin, ifosfamide, Gemzar (gemcitabine), Taxotere (docetaxel), Temodar (temozolomide) and DTIC (dacarbazine) - which are used interchangeably possibly in single agent chemotherapy or in combination regimens. depending upon the risk group and stage of the tumor. These drugs have been moderately effective in meeting the current unmet need, but their safety and efficacy profiles reveal a need for more effective and tolerable therapies. New treatment options will be able to exploit this significant unmet need.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Leiomyosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&companyID=sbwire

The leiomyosarcoma market is at present underserved by off-label generic drugs, which are used as there is no standard therapy for leiomyosarcoma. The leiomyosarcoma pipeline is strong, and contains only first-in-class molecules. These pipeline molecules may change the future treatment landscape for leiomyosarcoma. Some promising molecules in clinical development include ridaforolimus, Yondelis (trabectedin), Votrient (paopanib), TH-302 and Halaven (eribulin mesylate). These are highly targeted therapies with very low toxicity, and have distinct advantages over the currently used products in terms of better disease management.

GlobalData’s analysis indicates that the unmet need for leiomyosarcoma treatment is high due to the lack of standardized treatment. The current drug regimens used in the treatment of leiomyosarcoma have moderate efficacy but very low safety profiles. As a result, there is a need for drugs with novel mechanisms of action to treat the underlying cause of the disease. The future leiomyosarcoma therapeutics market will provide huge opportunities for new entrants due to two primary underlying reasons: there is significant need to improve outcomes for high and intermediate risk patients; and an increasing need for targeted therapies with novel mechanisms of action, with improved safety and toxicity profiles.

GlobalData, the industry analysis specialist, has released its new report, “Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Leiomyosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Leiomyosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Leiomyosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Leiomyosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782